A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration (Q33235813)

24 July 2017

1 reference

title

A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration (English)

1 reference

24 July 2017

Jason Wickens

1

1 reference

24 July 2017

Kevin J Blinder

series ordinal

2

1 reference

24 July 2017

publication date

1 January 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

29

1 reference

24 July 2017

issue

3

1 reference

24 July 2017

page(s)

189-199

1 reference

https://api.crossref.org/works/10.2165/00002018-200629030-00003

24 July 2017

1 reference

Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165/00002018-200629030-00003

Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165/00002018-200629030-00003

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic

21 January 2018

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy an

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

12 December 2020

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case

1 reference

12 December 2020

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

1 reference

12 December 2020

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

1 reference

12 December 2020

Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11.

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization

1 reference

12 December 2020

AL-3789: a novel ophthalmic angiostatic steroid

1 reference

12 December 2020

1 reference

12 December 2020

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

12 December 2020

Age-related macular degeneration

1 reference

12 December 2020

Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group

1 reference

12 December 2020

Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes

1 reference

12 December 2020

1 reference

12 December 2020

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data

1 reference

12 December 2020

Pegaptanib for neovascular age-related macular degeneration

1 reference

12 December 2020

The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization

1 reference

12 December 2020

Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.

1 reference

12 December 2020

Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group

1 reference

12 December 2020

Clinical pharmacokinetics of verteporfin

1 reference

12 December 2020

Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update

1 reference

12 December 2020

Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration

1 reference

12 December 2020

Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therap

1 reference

12 December 2020

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

1 reference

12 December 2020

A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results

1 reference

12 December 2020

Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

1 reference

12 December 2020

Intravitreal triamcinolone acetonide in exudative age-related macular degeneration

1 reference

12 December 2020

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

1 reference

12 December 2020

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients

1 reference

12 December 2020

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

1 reference

12 December 2020

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

1 reference

12 December 2020

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

1 reference

12 December 2020

10.2165/00002018-200629030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

24 July 2017

1026306124

0 references

1 reference